Corbett v. PharmaCare U.S., Inc.

District Court, S.D. California·Decided July 20, 2022·No. 3:21-cv-00137·Unknown

Opinion

MONTIQUENO CORBETT, DAMARIS Case No.: 21cv137-GPC(AGS) LUCIANO, and ROB DOBBS, individually and on behalf of all others ORDER RE; PLAINTIFFS’ MOTION similarly situated, FOR VOLUNTARY DIMISSAL OF PLAINTIFF DAMARIS LUCIANO Plaintiffs, WITHOUT PREJUDICE v. [Dkt. No. 59.] Defendant. Before the Court is Plaintiffs’ motion for voluntary dismissal of Plaintiff Damaris Luciano pursuant to Federal Rule of Civil Procedure 41(a)(2). (Dkt. No. 59.) Defendant filed an opposition to which Plaintiffs replied. (Dkt. Nos. 69, 73.) The Court finds that the matter is appropriate for decision without oral argument pursuant to Local Civ. R. 7.1(d)(1). Based on the reasoning below, the Court intends to GRANT Plaintiffs’ motion for voluntary dismissal of Plaintiff Damaris Luciano without prejudice on the condition that she responds to discovery requests. On January 25, 2021, Plaintiffs Montiqueno Corbett (“Corbett”), Damaris Luciano (“Luciano”) and Rob Dobbs (“Dobbs”) (collectively “Plaintiffs”) filed a putative class action complaint against Defendant PharmaCare U.S., Inc. (“Defendant” or “PharmaCare”) for violations of consumer fraud statutes for its sale of Sambucol, a dietary supplement that contains a proprietary extract of black elderberry. (Dkt. No. 1, Compl.) On June 17, 2021, the Court granted in part and denied in part Defendant’s motion to dismiss the complaint. (Dkt. No. 29.) On July 7, 2021, Plaintiffs filed a first amended putative class action complaint (“FAC”). (Dkt. No. 31, FAC.) On October 19, 2021, the Court granted in part and denied in part Defendant’s motion to dismiss the FAC. (Dkt. No. 44.) Specifically, the Court granted dismissal of California’s Consumer Legal Remedies Act claim for damages and the cause of action under Mass. Gen. Law ch. 93A without prejudice for failing to comply with the notice provisions under both statutes. (Id. at 38.) After curing the deficiencies, the operative second amended putative class action complaint (“SAC”) was filed on November 29, 2021. (Dkt. No. 45.) On December 13, 2021, Defendant filed its answer. (Dkt. No. 47.) The operative SAC alleges seven causes of action based on the alleged misleading labeling, advertising and sale of twelve dietary supplement products (“Products”) under the name Sambucol for violations of 1) California’s Unfair Competition Law (“UCL”) pursuant to California Business & Professions Code section 17200 et seq. on behalf of a national class and the California subclass; 2) California’s False Advertising Law (“FAL”) under California Business & Profession Code section 17500 et seq. on behalf of the California subclass; 3) California’s Consumer Legal Remedies Act (“CLRA”) under California Civil Code section 1750 et seq. on behalf of the California subclass; 4) violations of Massachusetts General Laws Chapter 93A, section 2, Mass. Gen. Laws. Ch. 93A, § 2 (“M.G.L. ch. 93A”), on behalf of the Massachusetts subclass; 5) Missouri Merchandising Practices Act (“MMPA”) pursuant to Mo. Ann. Stat. section 407.010 et seq. on behalf of the Missouri subclass; 6) breach of express warranties on behalf of a national class and the subclasses; and 7) breach of the implied warranty of merchantability on behalf of a national class and the subclasses. (Dkt. No. 45, SAC.) Plaintiff Corbett is a resident and citizen of San Diego, California, Plaintiff Luciano is a resident and citizen of Holyoke, Massachusetts, and Plaintiff Dobbs is a resident and citizen of Florissant, Missouri. (Id. ¶¶ 14-16.) They all purchased certain of the Products at issue after being exposed to, saw and relied on Defendant’s materially misleading representations on either the Products’ packaging and labeling, on advertisements on T.V. or on websites. (Id. ¶¶ 80-102.) When they purchased the Products, they believed they were legally sold supplements and they all claim they experienced no improvement in their health after using the Products. (Id. ¶¶ 82, 83, 90, 91, 98, 99.) Plaintiffs seek to certify a national class defined as: “During the fullest period allowed by law, all persons in the United States who purchased the Products (the ‘National Class’) for personal use and not for resale.” (Id. ¶ 103.) They also seek to certify a California, Massachusetts and Missouri subclass. (Id.) A case management order was filed on January 26, 2022. (Dkt. No. 52.) On December 27, 2021, Defendant served the identical discovery requests to all Plaintiffs. (Dkt. No. 69-1, Ferrari Decl. ¶ 21; Dkt. No. 59-2, Soffin Decl. ¶ 2; Dkt. No. 73-1, Kashima Decl. ¶ 2.) Corbett and Dobbs timely responded to the discovery requests and sat for their depositions. (Dkt. No. 59-2, Soffin Decl. ¶ 4.) Despite a two-week extension stipulated by Defendant, Luciano did not provide any discovery responses by the February 9, 2022 deadline and has still not served any discovery responses; in addition, her counsel did not preserve her objections to Defendant’s discovery requests. (Dkt. No. 69-1, Ferrari Decl. ¶ 22.) Defendant made repeated requests for Luciano’s discovery responses. (Id. ¶ 26.) On February 24, 2022 Plaintiffs’ counsel indicated she “will be filing a notice of voluntary dismissal . . . without prejudice.” (Id.) However, because no dismissal was filed, on April 1, 2022, Defendant made a follow-up request. (Id. ¶ 27.) On April 7, 2022, Defendant sought a discovery conference with the Magistrate Judge. (Id. ¶ 28.) On April 11, 2022, the parties filed a joint letter brief on Defendant’s motion to compel Luciano to “(1) appear for a deposition before May 6, 2022; (2) serve, within 7 days, verified, written responses, without objections, to PharmaCare’s first set of interrogatories and first set of request for production; and (3) produce, within 10 days, all documents responsive to PharmaCare’s first set of requests for production, without objection. (Dkt. No. 56 at 1.1) Defendant argued that Luciano failed timely to respond or object to PharmaCare’s written discovery despite repeated follow-ups and failed to appear for a noticed deposition, and refuses to commit to any date for her deposition despite repeated follow-ups. (Id.) Even though Plaintiffs’ counsel indicated that Luciano intended to file a voluntary dismissal, no request was ever made so Defendant filed the motion to compel after defense counsel made a final request on April 1, 2022. (Id.) in opposition, Plaintiffs explained that “Luciano has held more than one job at a time to financially care for her family since the inception of this litigation. Her current job working as a nightshift nurse (just one of her jobs), coupled with her parental responsibilities, only allow her to sleep four hours a night during her shifts. This has made it incredibly difficult for her to carry out her responsibilities as a class representative and to timely/regularly communicate with Plaintiffs’ counsel.” (Id. at 2.) “In February 2022, Plaintiffs’ counsel informed Defendant that they had been unable to reach Ms. Luciano. However, in early March 2022, after multiple unproductive attempts to maintain regular contact, Ms. Luciano reemerged and expressed a renewed commitment to this litigation. Following that assurance, Ms. Luciano again became uncommunicative.” (Id.) At the time, Plaintiffs’ counsel contemplated filing a motion to withdraw as counsel. (Id.) On April 8, 2022, Plaintiffs’ counsel was able to speak with Luciano where she agreed to dismiss her individual claims without prejudice so that she could participate as an absent class member. (Id. at 3.) Three minutes after the phone call, Plaintiffs’ counsel informed defense counsel of their intent to dismiss Luciano from the action, without prejudice and requested Defendant’s agreement to stipulate to a dismissal. Plaintiffs’ counsel also informed defense counsel that while they understood Luciano’s individual claims may be dismissed without prejudice, they anticipated taking s

Free access — add to your briefcase to read the full text and ask questions with AI

Corbett v. PharmaCare U.S., Inc., (S.D. Cal. 2022).

Corbett v. PharmaCare U.S., Inc. (Corbett v. PharmaCare U.S., Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related